Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment

Clinical Cancer Research

Volumn 19, Issue 2, 2013, Pages 480-490

  Nardi, Valentina ^a   Sadow, Peter M ^a,b   Juric, Dejan ^a,b,c   Zhao, Dave ^c   Cosper, Arjola K ^a   Bergethon, Kristin ^a   Scialabba, Vanessa L ^a   Batten, Julie M ^a   Borger, Darrell R ^b,c   Iafrate, Anthony John ^a,b   Heist, Rebecca S ^a,b,c   Lawrence, Donald P ^a,b,c   Flaherty, Keith T ^a,b,c   Bendell, Johanna C ^e   Deschler, Daniel ^b,d   Li, Yi ^c,f   Wirth, Lori J ^a,b,c   Dias Santagata, Dora ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARBOPLATIN; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GSK 1123212; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAF GENE; BRAIN METASTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; GENOTYPING TECHNIQUE; HER2 GENE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PAROTIDECTOMY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PRIORITY JOURNAL; SALIVARY DUCT CARCINOMA; SALIVARY GLAND CARCINOMA; SNAPSHOT GENOTYPING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, DUCTAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, ERBB-2; SALIVARY GLAND NEOPLASMS; YOUNG ADULT;

EID: 84872508720     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1842     Document Type: Article

References (49)

1. Speight PM, Barrett AW. Salivary gland tumours. Oral Dis 2002;8: 229-40.
2. Kane WJ, McCaffrey TV, Olsen KD, Lewis JE. Primary parotid malignancies. A clinical and pathologic review. Arch Otolaryngol Head Neck Surg 1991;117: 307-15.
3. Kleinsasser O, Klein HJ, Hubner G. [Salivary duct carcinoma. A group of salivary gland tumors analogous tomammary duct carcinoma]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 1968;192: 100-5.
4. Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 1994;78: 64-73.
5. Skalova A, Starek I, Kucerova V, Szepe P, Plank L. Salivary duct carcinoma - a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract 2001;197: 621-6.
6. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004;10: 944-6.
7. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005;103: 2526-33.
8. Williams MD, Roberts D, Blumenschein GR Jr, Temam S, Kies MS, Rosenthal DI, et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 2007;31: 1645-52.
9. Cornolti G, Ungari M, Morassi ML, Facchetti F, Rossi E, Lombardi D, et al. Amplification and overexpression of HER2/neu gene and HER2/ neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 2007;133: 1031-6.
10. Dagrada GP, Negri T, Tamborini E, Pierotti MA, Pilotti S. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2004;44: 301-2.
11. Johnson CJ, Barry MB, Vasef MA, Deyoung BR. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Appl Immunohistochem Mol Morphol 2008;16: 54-8.
12. Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 2009;45: 986-90.
13. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007;29: 907-12.
14. Skalova A, Starek I, Vanecek T, Kucerova V, Plank L, Szepe P, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003;42: 348-56.
15. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 2010;16: 2266-74.
16. Simpson RH, Desai S, Di Palma S. Salivary duct carcinoma in situ of the parotid gland. Histopathology 2008;53: 416-25.
17. Simpson RH, Prasad AR, Lewis JE, Skalova A, David L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol 2003;27: 1070-9.
18. McHugh JB, Visscher DW, Barnes EL. Update on selected salivary gland neoplasms. Arch Pathol Lab Med 2009;133: 1763-74.
19. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24: 2673-8.
20. Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol 2008;35: 309-19.
21. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2: 146-58.
22. Major Salivary Glands. Chapter 7. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
23. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25: 118-45.
24. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 2003;119: 801-6.
25. Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 2012;29: 704-6.
26. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996;77: 223-30.
27. Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 1997;19: 126-33.
28. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol 2010;33: 186-95.
29. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375: 377-84.
30. Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010;116: 2856-67.
31. Nashed M, Casasola RJ. Biological therapy of salivary duct carcinoma. J Laryngol Otol 2009;123: 250-2.
32. Prat A, Parera M, Reyes V, Peralta S, Cedres S, Andreu J, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 2008;30: 680-3.
33. Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT, et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 2011;29:e473-6.
34. Locati LD, Mela M, Quattrone P, Bossi P, Biffi A, Rinaldi G, et al. Antiandrogen therapy in recurrent and/or metastatic salivary glands carcinoma (RSGC). Ann Oncol 2003;14 Suppl 4:iv26.
35. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011;29: 4452-61.
36. Piha-Paul SA, Cohen PR, Kurzrock R. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 2011;29:e727-30.
37. Hollander MC, BlumenthalGM,Dennis PA.PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11: 289-301.
38. Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 2011;30: 3477-88.
39. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011; 13:224.
40. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010;467: 596-9.
41. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012;18: 4173-82.
42. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7: 1851-63.
43. Vultur A, Villanueva J, Herlyn M. BRAF inhibitor unveils its potential against advanced melanoma. Cancer Cell 2010;18: 301-2.
44. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12: 1441-6.
45. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68: 6084-91.
46. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54.
47. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-16.
48. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl J Med 2010;363: 809-19.
49. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366: 707-14.